Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 20/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 3/20 | 1.00 |
| ▸ | MAP4K4 | O95819 | 3/20 | 1.00 |
| ▸ | CSNK1A1 | P48729 | 3/20 | 1.00 |
| ▸ | CSNK1D | P48730 | 3/20 | 1.00 |
| ▸ | MINK1 | Q8N4C8 | 3/20 | 1.00 |
| ▸ | MAP4K5 | Q9Y4K4 | 3/20 | 1.00 |
| ▸ | PRKCA | P17252 | 2/20 | 1.00 |
| ▸ | PRKACA | P17612 | 2/20 | 1.00 |
| ▸ | HSPB1 | P04792 | 1/20 | 1.00 |
| ▸ | PRKCB | P05771 | 1/20 | 1.00 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.81 |
| ▸ | BRDT | Q58F21 | 3/20 | 0.81 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.80 |
| ▸ | LCK | P06239 | 2/20 | 0.80 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.80 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.80 |
| ▸ | PRKD2 | Q9BZL6 | 2/20 | 0.80 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.80 |
| ▸ | EGFR | P00533 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7767926 | 0.94 | MAPK14 (0.90) | MAPK14PRKD3MAP4K4CSNK1A1CSNK1D | |
| Sb-242235 SCHEMBL8660589 | 0.94 | MAPK14 (0.93) | MAPK14PRKD3MAP4K4CSNK1A1CSNK1D | |
| SCHEMBL7767982 | 0.91 | MAPK14 (0.84) | MAPK14PRKD3MAP4K4CSNK1A1CSNK1D | |
| SCHEMBL7773635 | 0.91 | MAPK14 (0.84) | MAPK14PRKD3MAP4K4CSNK1A1CSNK1D | |
| SCHEMBL4914492 | 0.91 | MAPK14 (1.00) | MAPK14PRKD3MAP4K4CSNK1A1CSNK1D | |
| SCHEMBL4916756 | 0.90 | MAPK14 (1.00) | MAPK14PRKD3MAP4K4CSNK1A1CSNK1D | |
| SCHEMBL4915397 | 0.90 | MAPK14 (1.00) | MAPK14PRKD3MAP4K4CSNK1A1CSNK1D | |
| SCHEMBL7772134 | 0.90 | MAPK14 (0.83) | MAPK14PRKD3MAP4K4CSNK1A1CSNK1D | |
| SCHEMBL7771968 | 0.90 | MAPK14 (0.83) | MAPK14PRKD3MAP4K4CSNK1A1CSNK1D | |
| SCHEMBL4919642 | 0.89 | MAPK14 (1.00) | MAPK14PRKD3MAP4K4CSNK1A1CSNK1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 233 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109951-A1 | METHODS AND COMPOSITIONS FOR INDUCING HEMATOPOIETIC CELL DIFFERENTIATION | FATE THERAPEUTICS INC (US) | 2026-04-23 | — | — | US | claimed |
| EP-4720261-A1 | NOVEL CULTURE CONDITIONS FOR CLONAL EXPANSION OF NEPHRON PROGENITOR CELLS, GENERATION OF NEPHRON ORGANOIDS, AND RAPID AND SCALABLE MODELING OF POLYCYSTIC KIDNEY DISEASE | University of Southern California (US) | 2026-04-08 | — | — | EP | claimed |
| EP-4587558-A1 | METHODS AND COMPOSITIONS FOR INDUCING HEMATOPOIETIC CELL DIFFERENTIATION | Fate Therapeutics, Inc. (US) | 2025-07-23 | — | — | EP | claimed |
| CN-119948152-A | Methods and compositions for inducing hematopoietic cell differentiation | 菲特治疗公司 | 2025-05-06 | — | — | CN | claimed |
| WO-2024243567-A1 | NOVEL CULTURE CONDITIONS FOR CLONAL EXPANSION OF NEPHRON PROGENITOR CELLS, GENERATION OF NEPHRON ORGANOIDS, AND RAPID AND SCALABLE MODELING OF POLYCYSTIC KIDNEY DISEASE | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2024-11-28 | — | — | WO | claimed |
| US-12145981-B2 | Methods and compounds for the treatment or prevention of severe influenza | Poolbeg Pharma (UK) Limited (GB) | 2024-11-19 | — | — | US | claimed |
| US-20240316055-A1 | METHODS FOR TREATING LEIGH SYNDROME | DBCC RES LLC (US) | 2024-09-26 | — | — | US | claimed |
| WO-2024059584-A1 | METHODS AND COMPOSITIONS FOR INDUCING HEMATOPOIETIC CELL DIFFERENTIATION | FATE THERAPEUTICS, INC. (US) | 2024-03-21 | — | — | WO | claimed |
| EP-3069732-B1 | DRUG FOR TREATING CORNEAL ENDOTHELIUM BY PROMOTING CELL PROLIFERATION OR INHIBITING CELL DAMAGE | THE DOSHISHA (JP) | 2023-07-12 | — | — | EP | claimed |
| US-20220275062-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OR PREVENTION OF SEVERE INFLUENZA | ORPH PHARMA IP COMPANY LIMITED (GB) | 2022-09-01 | — | — | US | claimed |
| US-11339207-B2 | Methods and compounds for the treatment or prevention of severe influenza | ORPH PHARMA IP COMPANY LIMITED (GB) | 2022-05-24 | — | — | US | claimed |
| EP-3553169-B1 | NORMALIZATION OF CULTURE OF CORNEAL ENDOTHELIAL CELLS | KYOTO PREFECTURAL PUBLIC UNIV CORP (JP) | 2021-11-03 | — | — | EP | claimed |
| US-20160331736-A1 | DRUG FOR TREATING CORNEAL ENDOTHELIUM BY PROMOTING CELL PROLIFERATION OR INHIBITING CELL DAMAGE | THE DOSHISHA (JP) | 2016-11-17 | — | — | US | claimed |
| EP-3069732-A1 | DRUG FOR TREATING CORNEAL ENDOTHELIUM BY PROMOTING CELL PROLIFERATION OR INHIBITING CELL DAMAGE | The Doshisha (JP) | 2016-09-21 | — | — | EP | claimed |
| US-20040097473-A1 | Use of p38 inhibitors for the treatment of smoke inhalation | SMITHKLINE BEECHAM CORPORATION | 2004-05-20 | — | — | US | claimed |
| US-20040092532-A1 | Use of p38 inhibitors for the treatment of smoke inhalation | SMITHKLINE BEECHAM CORPORATION | 2004-05-13 | — | — | US | claimed |
| EP-0935465-B1 | NOVEL SUBSTITUTED IMIDAZOLE COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2004-04-14 | — | — | EP | claimed |
| US-5811549-A | Process of preparing imidazole compounds | SMITHKLINE BEECHAM (US) | 1998-09-22 | — | — | US | claimed |
| US-5716955-A | Substituted imidazole compounds | SMITHKLINE BEECHAM CORPORATION (US) | 1998-02-10 | — | — | US | claimed |
| US-20260144674-A1 | Apparatus and Methods for Drug Delivery Using Microneedles | CLEARSIDE BIOMEDICAL, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| US-20260132471-A1 | GENOMIC BIOMARKERS OF EARLY RECURRENCE IN COLORECTAL CANCER (CRC) | FOUNDATION MEDICINE, INC. (US) | 2026-05-14 | — | — | US | disclosed |
| US-20260115177-A1 | MEDICINAL PRODUCTS AND METHODS FOR THE ALLEVIATION OF CANCER IMMUNOTHERA-PY-ASSOCIATED CYTOKINE RELEASE SYNDROME | POOLBEG PHARMA UK LTD (GB) | 2026-04-30 | — | — | US | disclosed |
| US-20260109951-A1 | METHODS AND COMPOSITIONS FOR INDUCING HEMATOPOIETIC CELL DIFFERENTIATION | FATE THERAPEUTICS INC (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4720261-A1 | NOVEL CULTURE CONDITIONS FOR CLONAL EXPANSION OF NEPHRON PROGENITOR CELLS, GENERATION OF NEPHRON ORGANOIDS, AND RAPID AND SCALABLE MODELING OF POLYCYSTIC KIDNEY DISEASE | University of Southern California (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20260034177-A1 | HUMAN FUNCTIONAL CORNEAL ENDOTHELIAL CELL AND APPLICATION THEREOF | KYOTO PREFECTURAL PUBLIC UNIV CORP (JP) | 2026-02-05 | — | — | US | disclosed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| EP-4648772-A1 | MEDICINAL PRODUCTS AND METHODS FOR THE ALLEVIATION OF CANCER IMMUNOTHERAPY-ASSOCIATED CYTOKINE RELEASE SYNDROME | Poolbeg Pharma (UK) Limited (GB) | 2025-11-19 | — | — | EP | disclosed |
| US-20250345206-A1 | APPARATUS AND METHODS FOR OCULAR INJECTION | CLEARSIDE BIOMEDICAL, INC. (US) | 2025-11-13 | — | — | US | disclosed |
| US-20250302883-A1 | NORMALIZATION OF CULTURE OF CORNEAL ENDOTHELIAL CELLS | KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION (JP) | 2025-10-02 | — | — | US | disclosed |
| EP-4587558-A1 | METHODS AND COMPOSITIONS FOR INDUCING HEMATOPOIETIC CELL DIFFERENTIATION | Fate Therapeutics, Inc. (US) | 2025-07-23 | — | — | EP | disclosed |
| US-12350261-B2 | Methods and devices for the treatment of ocular diseases in human subjects | CLEARSIDE BIOMEDICAL, INC. (US) | 2025-07-08 | — | — | US | disclosed |
| WO-2025128887-A1 | METHODS AND COMPOSITIONS FOR SELECTIVE ENRICHMENT OF METHYLATION SIGNAL | FOUNDATION MEDICINE, INC. (US) | 2025-06-19 | — | — | WO | disclosed |
| US-20250201339-A1 | USE OF COMBINED CD274 COPY NUMBER CHANGES AND TMB TO PREDICT RESPONSE TO IMMUNOTHERAPIES | FOUNDATION MEDICINE, INC. (US) | 2025-06-19 | — | — | US | disclosed |
| US-20250186253-A1 | DEVICES AND METHODS FOR ADJUSTING THE INSERTION DEPTH OF A NEEDLE FOR MEDICAMENT DELIVERY | CLEARSIDE BIOMEDICAL, INC. (US) | 2025-06-12 | — | — | US | disclosed |
| WO-2025122500-A1 | ESR1 GENE FUSIONS AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2025-06-12 | — | — | WO | disclosed |
| WO-2025122504-A1 | ESR1 MUTATIONS, ESR1 CO-OCCURRING MUTATIONS, AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2025-06-12 | — | — | WO | disclosed |
| WO-2025122856-A1 | USE OF FIBROBLAST GROWTH FACTOR RECEPTOR 3 MUTATIONS AND TUMOR MUTATIONAL BURDEN TO PREDICT RESPONSE TO IMMUNOTHERAPIES | FOUNDATION MEDICINE, INC. (US) | 2025-06-12 | — | — | WO | disclosed |
| EP-4566672-A2 | METHODS FOR THE TREATMENT OF OCULAR DISEASE IN HUMAN SUBJECTS | Clearside Biomedical Inc. (US) | 2025-06-11 | — | — | EP | disclosed |
| EP-3554435-B1 | SYSTEMS FOR DELIVERING DRUGS TO RETINAL TISSUE | CLEARSIDE BIOMEDICAL INC (US) | 2025-06-04 | — | — | EP | disclosed |
| US-20250152413-A1 | SYSTEMS, DEVICES, AND METHODS FOR NEEDLE-LESS OCULAR INJECTIONS | CLEARSIDE BIOMEDICAL INC (US) | 2025-05-15 | — | — | US | disclosed |
| US-20250149116-A1 | ABL1 FUSIONS AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2025-05-08 | — | — | US | disclosed |
| EP-4547709-A2 | RET GENE FUSIONS AND USES THEREOF | Foundation Medicine, Inc. (US) | 2025-05-07 | — | — | EP | disclosed |
| CN-119948152-A | Methods and compositions for inducing hematopoietic cell differentiation | 菲特治疗公司 | 2025-05-06 | — | — | CN | disclosed |
| US-20250129429-A1 | GENE FUSIONS IN SARCOMA | FOUNDATION MEDICINE, INC. (US) | 2025-04-24 | — | — | US | disclosed |
| EP-4532025-A1 | IGF1R ACTIVATION MUTATIONS AND USES THEREOF | Foundation Medicine, Inc. (US) | 2025-04-09 | — | — | EP | disclosed |
| US-20250084482-A1 | METHODS OF USING SOMATIC HLA-I LOH TO PREDICT RESPONSE OF IMMUNE CHECKPOINT INHIBITOR-TREATED PATIENTS WITH LUNG CANCER | FOUNDATION MEDICINE, INC. (US) | 2025-03-13 | — | — | US | disclosed |
| US-20250059585-A1 | METHODS OF REMOVING EMBEDDING AGENTS FROM EMBEDDED SAMPLES | FOUNDATION MEDICINE, INC. (US) | 2025-02-20 | — | — | US | disclosed |
| EP-3721872-B1 | METHODS FOR THE TREATMENT OF OCULAR DISEASE IN HUMAN SUBJECTS | CLEARSIDE BIOMEDICAL INC (US) | 2025-01-22 | — | — | EP | disclosed |
| US-12201558-B2 | Apparatus and methods for ocular injection | CLEARSIDE BIOMEDICAL, INC. (US) | 2025-01-21 | — | — | US | disclosed |
| US-20250011400-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OR PREVENTION OF SEVERE INFLUENZA | Poolbeg Pharma (UK) Limited (GB) | 2025-01-09 | — | — | US | disclosed |
| US-20250003009-A1 | FRAGMENT CONSENSUS METHODS FOR ULTRASENSITIVE DETECTION OF ABERRANT METHYLATION | FOUNDATION MEDICINE, INC. (US) | 2025-01-02 | — | — | US | disclosed |
| US-20250002844-A1 | GENERATION AND MAINTENANCE OF STEM CELLS | THE SCRIPPS RESEARCH INSTITUTE | 2025-01-02 | — | — | US | disclosed |
| WO-2024243567-A1 | NOVEL CULTURE CONDITIONS FOR CLONAL EXPANSION OF NEPHRON PROGENITOR CELLS, GENERATION OF NEPHRON ORGANOIDS, AND RAPID AND SCALABLE MODELING OF POLYCYSTIC KIDNEY DISEASE | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2024-11-28 | — | — | WO | disclosed |
| WO-2024238675-A2 | GENOMIC BIOMARKERS OF EARLY RECURRENCE IN COLORECTAL CANCER (CRC) | FOUNDATION MEDICINE, INC. (US) | 2024-11-21 | — | — | WO | disclosed |
| EP-4463571-A1 | ALK GENE FUSIONS AND USES THEREOF | Foundation Medicine, Inc. (US) | 2024-11-20 | — | — | EP | disclosed |
| US-12145981-B2 | Methods and compounds for the treatment or prevention of severe influenza | Poolbeg Pharma (UK) Limited (GB) | 2024-11-19 | — | — | US | disclosed |
| US-12127975-B2 | Devices and methods for adjusting the insertion depth of a needle for medicament delivery | CLEARSIDE BIOMEDICAL, INC. (US) | 2024-10-29 | — | — | US | disclosed |
| EP-4448759-A2 | METHODS OF REMOVING EMBEDDING AGENTS FROM EMBEDDED SAMPLES | Foundation Medicine, Inc. (US) | 2024-10-23 | — | — | EP | disclosed |
| EP-3496680-B1 | DEVICE FOR ADJUSTING THE INSERTION DEPTH OF A NEEDLE FOR MEDICAMENT DELIVERY | CLEARSIDE BIOMEDICAL INC (US) | 2024-10-02 | — | — | EP | disclosed |
| US-20240316055-A1 | METHODS FOR TREATING LEIGH SYNDROME | DBCC RES LLC (US) | 2024-09-26 | — | — | US | disclosed |
| EP-4433607-A1 | FRAGMENT CONSENSUS METHODS FOR ULTRASENSITIVE DETECTION OF ABERRANT METHYLATION | Foundation Medicine, Inc. (US) | 2024-09-25 | — | — | EP | disclosed |
| CN-114748622-B | P38 kinase inhibitors reduce DUX4 and downstream gene expression and treat FSHD | 弗尔康医疗公司 | 2024-09-24 | — | — | CN | disclosed |
| EP-4423302-A2 | NOVEL KINASE FUSIONS DETECTED BY LIQUID BIOPSY | Foundation Medicine, Inc. (US) | 2024-09-04 | — | — | EP | disclosed |
| CN-114732910-B | P38 kinase inhibitors reduce DUX4 and downstream gene expression and treat FSHD | 弗尔康医疗公司 | 2024-08-23 | — | — | CN | disclosed |
| WO-2024168146-A1 | BRAF GENE FUSIONS AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| US-20240263240-A1 | CD274 MUTATIONS FOR CANCER TREATMENT | FOUNDATION MEDICINE, INC. (US) | 2024-08-08 | — | — | US | disclosed |
| US-12054741-B2 | Generation and maintenance of stem cells | THE SCRIPPS RESEARCH INSTITUTE (US) | 2024-08-06 | — | — | US | disclosed |
| CN-118451193-A | Method for removing embedding agent from embedding sample | 基金会医学公司 | 2024-08-06 | — | — | CN | disclosed |
| CN-118414436-A | Fragment identity method for ultrasensitive detection of aberrant methylation | 基金会医学公司 | 2024-07-30 | — | — | CN | disclosed |
| CN-118414439-A | Novel kinase fusion by liquid biopsy | 基金会医学公司 | 2024-07-30 | — | — | CN | disclosed |
| WO-2024150014-A1 | MEDICINAL PRODUCTS AND METHODS FOR THE ALLEVIATION OF CANCER IMMUNOTHERAPY-ASSOCIATED CYTOKINE RELEASE SYNDROME | Poolbeg Pharma (UK) Limited (GB) | 2024-07-18 | — | — | WO | disclosed |
| WO-2023178290-A9 | USE OF COMBINED CD274 COPY NUMBER CHANGES AND TMB TO PREDICT RESPONSE TO IMMUNOTHERAPIES | FOUNDATION MEDICINE, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| EP-4378444-A2 | APPARATUS AND METHODS FOR OCULAR INJECTION | Clearside Biomedical, Inc. (US) | 2024-06-05 | — | — | EP | disclosed |
| EP-4359570-A1 | METHODS OF USING SOMATIC HLA-I LOH TO PREDICT RESPONSE OF IMMUNE CHECKPOINT INHIBITOR-TREATED PATIENTS WITH LUNG CANCER | Foundation Medicine, Inc. (US) | 2024-05-01 | — | — | EP | disclosed |
| US-20240110230-A1 | BIOMARKERS FOR CANCER TREATMENT | FOUNDATION MEDICINE, INC. (US) | 2024-04-04 | — | — | US | disclosed |
| US-20240093304-A1 | ALK FUSION GENES AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2024-03-21 | — | — | US | disclosed |
| WO-2024059584-A1 | METHODS AND COMPOSITIONS FOR INDUCING HEMATOPOIETIC CELL DIFFERENTIATION | FATE THERAPEUTICS, INC. (US) | 2024-03-21 | — | — | WO | disclosed |
| EP-4337795-A2 | CD274 MUTATIONS FOR CANCER TREATMENT | Foundation Medicine, Inc. (US) | 2024-03-20 | — | — | EP | disclosed |
| EP-3417896-B1 | APPARATUS AND METHODS FOR OCULAR INJECTION | CLEARSIDE BIOMEDICAL INC (US) | 2024-01-24 | — | — | EP | disclosed |
| WO-2024015652-A1 | SYSTEMS, DEVICES, AND METHODS FOR NEEDLE-LESS OCULAR INJECTIONS | CLEARSIDE BIOMEDICAL, INC. (US) | 2024-01-18 | — | — | WO | disclosed |
| WO-2024007015-A2 | RET GENE FUSIONS AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2024-01-04 | — | — | WO | disclosed |
| EP-4291902-A2 | BIOMARKERS FOR CANCER TREATMENT | Foundation Medicine, Inc. (US) | 2023-12-20 | — | — | EP | disclosed |
| WO-2023235822-A1 | IGF1R ACTIVATION MUTATIONS AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2023-12-07 | — | — | WO | disclosed |
| WO-2023230444-A2 | ABL1 FUSIONS AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2023-11-30 | — | — | WO | disclosed |
| US-20230363941-A1 | APPARATUS AND METHODS OF RETINAL INJECTION | CLEARSIDE BIOMEDICAL, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| EP-4271831-A1 | ALK FUSION GENES AND USES THEREOF | Foundation Medicine, Inc. (US) | 2023-11-08 | — | — | EP | disclosed |
| EP-3413851-B1 | PACKAGING | CLEARSIDE BIOMEDICAL INC (US) | 2023-09-27 | — | — | EP | disclosed |
| WO-2023178290-A1 | USE OF COMBINED CD274 COPY NUMBER CHANGES AND TMB TO PREDICT RESPONSE TO IMMUNOTHERAPIES | FOUNDATION MEDICINE, INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| US-20230295734-A1 | BCOR REARRANGEMENTS AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| WO-2022241293-A9 | CD274 MUTATIONS FOR CANCER TREATMENT | FOUNDATION MEDICINE, INC. (US) | 2023-08-24 | — | — | WO | disclosed |
| EP-4225235-A1 | APPARATUS AND METHODS OF RETINAL INJECTION | Clearside Biomedical, Inc. (US) | 2023-08-16 | — | — | EP | disclosed |
| EP-4218773-A1 | HUMAN FUNCTIONAL CORNEAL ENDOTHELIAL CELL AND APPLICATION THEREOF | Kyoto Prefectural Public University Corporation (JP) | 2023-08-02 | — | — | EP | disclosed |
| WO-2023137447-A1 | ALK GENE FUSIONS AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2023-07-20 | — | — | WO | disclosed |
| US-20230223105-A1 | MITIGATION OF STATISTICAL BIAS IN GENETIC SAMPLING | FOUNDATION MEDICINE, INC. (US) | 2023-07-13 | — | — | US | disclosed |
| EP-3069732-B1 | DRUG FOR TREATING CORNEAL ENDOTHELIUM BY PROMOTING CELL PROLIFERATION OR INHIBITING CELL DAMAGE | THE DOSHISHA (JP) | 2023-07-12 | — | — | EP | disclosed |
| CN-116327482-A | Apparatus and method for ocular injection | 科尼尔赛德生物医学公司 | 2023-06-27 | — | — | CN | disclosed |
| WO-2023114948-A2 | METHODS OF REMOVING EMBEDDING AGENTS FROM EMBEDDED SAMPLES | FOUNDATION MEDICINE, INC. (US) | 2023-06-22 | — | — | WO | disclosed |
| US-20230157869-A1 | APPARATUS AND METHODS FOR OCULAR INJECTION | CLEARSIDE BIOMEDICAL, INC. (US) | 2023-05-25 | — | — | US | disclosed |
| WO-2023092097-A1 | FRAGMENT CONSENSUS METHODS FOR ULTRASENSITIVE DETECTION OF ABERRANT METHYLATION | FOUNDATION MEDICINE, INC. (US) | 2023-05-25 | — | — | WO | disclosed |
| WO-2023084459-A1 | METHODS OF TREATING SARS-COV-2 | PFIZER INC. (US) | 2023-05-19 | — | — | WO | disclosed |
| WO-2023077104-A2 | NOVEL KINASE FUSIONS DETECTED BY LIQUID BIOPSY | FOUNDATION MEDICINE, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| CN-110302004-B | Apparatus and method for ocular injection | 科尼尔赛德生物医学公司 | 2023-04-28 | — | — | CN | disclosed |
| EP-4159212-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | Fulcrum Therapeutics, Inc. (US) | 2023-04-05 | — | — | EP | disclosed |
| EP-3416658-B1 | HUMAN FUNCTIONAL CORNEAL ENDOTHELIAL CELL AND APPLICATION THEREOF | KYOTO PREFECTURAL PUBLIC UNIV CORP (JP) | 2023-03-22 | — | — | EP | disclosed |
| US-20230083551-A1 | Formulations for the Suprachoroidal Space of an Eye and Methods | EMORY UNIVERSITY | 2023-03-16 | — | — | US | disclosed |
| US-11596545-B2 | Systems and methods for ocular drug delivery | CLEARSIDE BIOMEDICAL, INC. (US) | 2023-03-07 | — | — | US | disclosed |
| US-20230057984-A1 | NORMALIZATION OF CULTURE OF CORNEAL ENDOTHELIAL CELLS | KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION (JP) | 2023-02-23 | — | — | US | disclosed |
| US-11559428-B2 | Apparatus and methods for ocular injection | CLEARSIDE BIOMEDICAL, INC. (US) | 2023-01-24 | — | — | US | disclosed |
| EP-4114979-A2 | BCOR REARRANGEMENTS AND USES THEREOF | Foundation Medicine, Inc. (US) | 2023-01-11 | — | — | EP | disclosed |
| EP-4110378-A1 | MITIGATION OF STATISTICAL BIAS IN GENETIC SAMPLING | Foundation Medicine, Inc. (US) | 2023-01-04 | — | — | EP | disclosed |
| WO-2022272309-A1 | METHODS OF USING SOMATIC HLA-I LOH TO PREDICT RESPONSE OF IMMUNE CHECKPOINT INHIBITOR-TREATED PATIENTS WITH LUNG CANCER | FOUNDATION MEDICINE, INC. (US) | 2022-12-29 | — | — | WO | disclosed |
| US-20220392638-A1 | PRECISION ENRICHMENT OF PATHOLOGY SPECIMENS | FOUNDATION MEDICINE, INC. (US) | 2022-12-08 | — | — | US | disclosed |
| US-11518981-B2 | Methods of enhancing engraftment activity of hematopoietic stem cells | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2022-12-06 | — | — | US | disclosed |
| CN-115427069-A | Reducing statistical bias in genetic sampling | 基金会医学公司 | 2022-12-02 | — | — | CN | disclosed |
| EP-2887982-B1 | APPARATUS FOR DRUG DELIVERY USING MICRONEEDLES | CLEARSIDE BIOMEDICAL INC (US) | 2022-11-23 | — | — | EP | disclosed |
| US-11504431-B2 | Formulations for the suprachoroidal space of an eye and methods | EMORY UNIVERSITY (US) | 2022-11-22 | — | — | US | disclosed |
| WO-2022241293-A2 | CD274 MUTATIONS FOR CANCER TREATMENT | FOUNDATION MEDICINE, INC. (US) | 2022-11-17 | — | — | WO | disclosed |
| WO-2021174052-A9 | MITIGATION OF STATISTICAL BIAS IN GENETIC SAMPLING | FOUNDATION MEDICINE, INC. (US) | 2022-10-20 | — | — | WO | disclosed |
| US-20220280341-A1 | APPARATUS AND METHODS FOR DRUG DELIVERY USING MICRONEEDLES | CLEARSIDE ROYALTY LLC | 2022-09-08 | — | — | US | disclosed |
| US-20220280386-A1 | METHODS AND APPARATUS FOR EXTRACTING FLUID FROM CONTAINER | CLEARSIDE BIOMEDICAL, INC. | 2022-09-08 | — | — | US | disclosed |
| US-20220282254-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | FULCRUM THERAPEUTICS INC (US) | 2022-09-08 | — | — | US | disclosed |
| US-20220275062-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OR PREVENTION OF SEVERE INFLUENZA | ORPH PHARMA IP COMPANY LIMITED (GB) | 2022-09-01 | — | — | US | disclosed |
| WO-2022174234-A2 | BIOMARKERS FOR CANCER TREATMENT | FOUNDATION MEDICINE, INC. (US) | 2022-08-18 | — | — | WO | disclosed |
| US-20220244263-A1 | METHODS FOR TREATING SMALL CELL NEUROENDOCRINE AND RELATED CANCERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-08-04 | — | — | US | disclosed |
| CN-114748622-A | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD | 弗尔康医疗公司 | 2022-07-15 | — | — | CN | disclosed |
| CN-114732910-A | P38 kinase inhibitor reduces DUX4 and downstream gene expression for treatment of FSHD | 弗尔康医疗公司 | 2022-07-12 | — | — | CN | disclosed |
| WO-2022147163-A1 | ALK FUSION GENES AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2022-07-07 | — | — | WO | disclosed |
| US-11339207-B2 | Methods and compounds for the treatment or prevention of severe influenza | ORPH PHARMA IP COMPANY LIMITED (GB) | 2022-05-24 | — | — | US | disclosed |
| US-20220133704-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | FULCRUM THERAPEUTICS INC (US) | 2022-05-05 | — | — | US | disclosed |
| US-20220133704-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | FULCRUM THERAPEUTICS INC (US) | 2022-05-05 | — | — | US | disclosed |
| CN-111601593-B | P38 kinase inhibitor reduces DUX4 and downstream gene expression for treatment of FSHD | 弗尔康医疗公司 | 2022-04-15 | — | — | CN | disclosed |
| WO-2022076938-A1 | APPARATUS AND METHODS OF RETINAL INJECTION | CLEARSIDE BIOMEDICAL, INC. (US) | 2022-04-14 | — | — | WO | disclosed |
| US-11291659-B2 | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD | Fulcrum Therapeutics, Inc. (US) | 2022-04-05 | — | — | US | disclosed |
| US-11291659-B2 | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD | Fulcrum Therapeutics, Inc. (US) | 2022-04-05 | — | — | US | disclosed |
| US-20220096602-A1 | LIF THERAPY FOR INDUCING INTESTINAL EPITHELIAL CELL REGENERATION | UNIV RUTGERS (US) | 2022-03-31 | — | — | US | disclosed |
| US-11154543-B2 | P38 MAP kinase inhibitors for wound healing | THE SCHEPENS EYE RESEARCH INSTITUTE, INC. (US) | 2021-10-26 | — | — | US | disclosed |
| EP-2799537-B1 | NORMALIZATION OF CULTURE OF CORNEAL ENDOTHELIAL CELLS | KYOTO PREFECTURAL PUBLIC UNIV CORP (JP) | 2021-09-22 | — | — | EP | disclosed |
| US-10980787-B2 | Drug for treating or preventing disorder caused by TGF-B signals, and application thereof | THE DOSHISHA (JP) | 2021-04-20 | — | — | US | disclosed |
| US-20210046124-A1 | HUMAN FUNCTIONAL CORNEAL ENDOTHELIAL CELL AND APPLICATION THEREOF | KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION (JP) | 2021-02-18 | — | — | US | disclosed |
| US-20200383963-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | Fulcrum Therapeutics, Inc. | 2020-12-10 | — | — | US | disclosed |
| US-10813920-B2 | Drug for treating corneal endothelium by promoting cell proliferation or inhibiting cell damage | THE DOSHISHA (JP) | 2020-10-27 | — | — | US | disclosed |
| EP-3081568-B1 | COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE | EIP PHARMA LLC (US) | 2019-11-13 | — | — | EP | disclosed |
| EP-3553169-A1 | NORMALIZATION OF CULTURE OF CORNEAL ENDOTHELIAL CELLS | Kyoto Prefectural Public University Corporation (JP) | 2019-10-16 | — | — | EP | disclosed |
| US-10342786-B2 | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD | Fulcrum Therapeutics, Inc. (US) | 2019-07-09 | — | — | US | disclosed |
| US-20190105312-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | Fulcrum Therapeutics, Inc. | 2019-04-11 | — | — | US | disclosed |
| WO-2019071147-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | Fulcrum Therapeutics, Inc. (US) | 2019-04-11 | — | — | WO | disclosed |
| US-20190105311-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | Fulcrum Therapeutics, Inc. | 2019-04-11 | — | — | US | disclosed |
| US-20190083543-A1 | HUMAN FUNCTIONAL CORNEAL ENDOTHELIAL CELL AND APPLICATION THEREOF | KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION (JP) | 2019-03-21 | — | — | US | disclosed |
| US-20180369220-A1 | DRUG FOR TREATING OR PREVENTING DISORDER CAUSED BY TGF-B SIGNALS, AND APPLICATION THEREOF | THE DOSHISHA (JP) | 2018-12-27 | — | — | US | disclosed |
| EP-3416658-A1 | HUMAN FUNCTIONAL CORNEAL ENDOTHELIAL CELL AND APPLICATION THEREOF | Kyoto Prefectural Public University Corporation (JP) | 2018-12-26 | — | — | EP | disclosed |
| EP-3381472-A1 | DRUG FOR TREATING OR PREVENTING DISORDER CAUSED BY TGF- SIGNALS, AND APPLICATION THEREOF | The Doshisha (JP) | 2018-10-03 | — | — | EP | disclosed |
| WO-2017141926-A1 | HUMAN FUNCTIONAL CORNEAL ENDOTHELIAL CELL AND APPLICATION THEREOF | KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION (JP) | 2017-08-24 | — | — | WO | disclosed |
| WO-2017066758-A1 | P38 MAP KINASE INHIBITORS FOR WOUND HEALING | THE SCHEPENS EYE RESEARCH INSTITUTE, INC. (US) | 2017-04-20 | — | — | WO | disclosed |
| US-20160354375-A1 | CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES SUCH AS TAUOPATHIES | ELECTROPHORETICS LIMITED (GB) | 2016-12-08 | — | — | US | disclosed |
| US-20160331736-A1 | DRUG FOR TREATING CORNEAL ENDOTHELIUM BY PROMOTING CELL PROLIFERATION OR INHIBITING CELL DAMAGE | THE DOSHISHA (JP) | 2016-11-17 | — | — | US | disclosed |
| EP-3081568-A1 | COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE | Eip Pharma, LLC (US) | 2016-10-19 | — | — | EP | disclosed |
| EP-3069732-A1 | DRUG FOR TREATING CORNEAL ENDOTHELIUM BY PROMOTING CELL PROLIFERATION OR INHIBITING CELL DAMAGE | The Doshisha (JP) | 2016-09-21 | — | — | EP | disclosed |
| US-9427438-B2 | Compositions and methods for treating Alzheimer's disease | EIP PHARMA, LLC (US) | 2016-08-30 | — | — | US | disclosed |
| US-9427438-B2 | Compositions and methods for treating Alzheimer's disease | EIP PHARMA, LLC (US) | 2016-08-30 | — | — | US | disclosed |
| EP-2707369-B1 | COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE | EIP PHARMA LLC (US) | 2016-07-27 | — | — | EP | disclosed |
| US-20160030431-A1 | COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE | EIP PHARMA, LLC | 2016-02-04 | — | — | US | disclosed |
| US-20160030431-A1 | COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE | EIP PHARMA, LLC | 2016-02-04 | — | — | US | disclosed |
| US-20150044178-A1 | NORMALIZATION OF CULTURE OF CORNEAL ENDOTHELIAL CELLS | KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION (JP) | 2015-02-12 | — | — | US | disclosed |
| US-20140357638-A1 | COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE | EIP PHARMA, LLC (US) | 2014-12-04 | — | — | US | disclosed |
| US-20140357638-A1 | COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE | EIP PHARMA, LLC (US) | 2014-12-04 | — | — | US | disclosed |
| EP-2799537-A1 | NORMALIZATION OF CULTURE OF CORNEAL ENDOTHELIAL CELLS | Kyoto Prefectural Public University Corporation (JP) | 2014-11-05 | — | — | EP | disclosed |
| WO-2013086002-A1 | COMPOSITIONS, PROCESS OF PREPARATION OF SAID COMPOSITIONS AND METHOD OF TREATING CANCER | CELLWORKS RESEARCH INDIA PRIVATE LIMITED (IN) | 2013-06-13 | — | — | WO | disclosed |
| WO-2013086002-A1 | COMPOSITIONS, PROCESS OF PREPARATION OF SAID COMPOSITIONS AND METHOD OF TREATING CANCER | CELLWORKS RESEARCH INDIA PRIVATE LIMITED (IN) | 2013-06-13 | — | — | WO | disclosed |
| WO-2012154814-A1 | COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE | EIP PHARMA, LLC (US) | 2012-11-15 | — | — | WO | disclosed |
| US-20120289511-A1 | COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE | EIP PHARMA, LLC (US) | 2012-11-15 | — | — | US | disclosed |
| US-20120289511-A1 | COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE | EIP PHARMA, LLC (US) | 2012-11-15 | — | — | US | disclosed |
| US-8242273-B2 | Synthesis of 4/5-pyrimidinylimidazoles via sequential functionalization of 2,4-dichloropyrimidine | JANSSEN PHARMACEUTICA, NV (BE) | 2012-08-14 | — | — | US | disclosed |
| US-8242273-B2 | Synthesis of 4/5-pyrimidinylimidazoles via sequential functionalization of 2,4-dichloropyrimidine | JANSSEN PHARMACEUTICA, NV (BE) | 2012-08-14 | — | — | US | disclosed |
| US-8124765-B2 | Synthesis of 4/5-pyrimidinylimidazoles via sequential functionalization of 2,4-dichloropyrimidine | JANSSEN PHARMACEUTICA, NV (BE) | 2012-02-28 | — | — | US | disclosed |
| US-8124765-B2 | Synthesis of 4/5-pyrimidinylimidazoles via sequential functionalization of 2,4-dichloropyrimidine | JANSSEN PHARMACEUTICA, NV (BE) | 2012-02-28 | — | — | US | disclosed |
| US-8003649-B2 | Bicyclic derivatives for use in the treatment of androgen receptor associated conditions-155 | ASTRAZENECA AB (SE) | 2011-08-23 | — | — | US | disclosed |
| US-20100274015-A1 | SYNTHESIS OF 4/5-PYRIMIDINYLIMIDAZOLES VIA SEQUENTIAL FUNCTIONALIZATION OF 2,4-DICHLOROPYRIMIDINE | DENG XIAOHU | 2010-10-28 | — | — | US | disclosed |
| US-20100274015-A1 | SYNTHESIS OF 4/5-PYRIMIDINYLIMIDAZOLES VIA SEQUENTIAL FUNCTIONALIZATION OF 2,4-DICHLOROPYRIMIDINE | DENG XIAOHU | 2010-10-28 | — | — | US | disclosed |
| US-20100274016-A1 | SYNTHESIS OF 4/5-PYRIMIDINYLIMIDAZOLES VIA SEQUENTIAL FUNCTIONALIZATION OF 2,4-DICHLOROPYRIMIDINE | DENG XIAOHU | 2010-10-28 | — | — | US | disclosed |
| US-20100274016-A1 | SYNTHESIS OF 4/5-PYRIMIDINYLIMIDAZOLES VIA SEQUENTIAL FUNCTIONALIZATION OF 2,4-DICHLOROPYRIMIDINE | DENG XIAOHU | 2010-10-28 | — | — | US | disclosed |
| EP-2235010-A1 | BICYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF ANDROGEN RECEPTOR ASSOCIATED CONDITIONS | AstraZeneca AB (SE) | 2010-10-06 | — | — | EP | disclosed |
| US-7807832-B2 | Synthesis of 4/5-pyrimidinylimidazoles via sequential functionalization of 2,4-dichloropyrimidine | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-05 | — | — | US | disclosed |
| US-7807832-B2 | Synthesis of 4/5-pyrimidinylimidazoles via sequential functionalization of 2,4-dichloropyrimidine | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-05 | — | — | US | disclosed |
| US-20100016279-A1 | BICYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF ANDROGEN RECEPTOR ASSOCIATED CONDITIONS-155 | ASTRAZENECA AB (SE) | 2010-01-21 | — | — | US | disclosed |
| EP-2116245-A2 | EGFR kinase inhibitor combinations for treating respiratory and gastrointestinal disorders | Boehringer Ingelheim International GmbH (DE) | 2009-11-11 | — | — | EP | disclosed |
| WO-2009081197-A1 | BICYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF ANDROGEN RECEPTOR ASSOCIATED CONDITIONS | ASTRAZENECA AB (SE) | 2009-07-02 | — | — | WO | disclosed |
| US-20090017036-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISORDERS | JUNG BIRGIT | 2009-01-15 | — | — | US | disclosed |
| US-20080119498-A1 | Therapeutic Agent for Pruritus Comprising P38 Map Kinase Inhibitor as the Active Ingredient | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| US-20080108658-A1 | METHODS OF PROMOTING OSTEOGENESIS | PROTTER ANDREW A | 2008-05-08 | — | — | US | disclosed |
| US-20080039461-A1 | Treatment of pain by inhibition of p38 map kinase | PROTTER ANDREW A | 2008-02-14 | — | — | US | disclosed |
| US-7268139-B2 | Methods of promoting osteogenesis | SCIOS, INC. (US) | 2007-09-11 | — | — | US | disclosed |
| US-7244441-B2 | Stents and intra-luminal prostheses containing map kinase inhibitors | SCIOS, INC. (US) | 2007-07-17 | — | — | US | disclosed |
| US-20070123516-A1 | Method of treating mucus hypersecretion | BOEHRINGER INGELHEIM PHARMA GMBH & CO., KG (DE) | 2007-05-31 | — | — | US | disclosed |
| EP-1784224-A2 | EGFR KINASE INHIBITOR COMBINATIONS FOR TREATING RESPIRATORY AND GASTROINTESTINAL DISORDERS | Boehringer Ingelheim International GmbH (DE) | 2007-05-16 | — | — | EP | disclosed |
| WO-2007016286-A1 | SYNTHESIS OF 4/5-PYRIMIDINYLIMIDAZOLES VIA SEQUENTIAL FUNCTIONALIZATION OF 2,4-DICHLOROPYRIMIDINE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-02-08 | — | — | WO | disclosed |
| US-20070027319-A1 | Synthesis of 4/5-pyrimidinylimidazoles via sequential functionalization of 2,4-dichloropyrimidine | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-02-01 | — | — | US | disclosed |
| US-20070027319-A1 | Synthesis of 4/5-pyrimidinylimidazoles via sequential functionalization of 2,4-dichloropyrimidine | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-02-01 | — | — | US | disclosed |
| EP-1707205-A2 | PHARMACEUTICAL COMPOSITIONS OF ANTICHOLINERGICS AND P38 KINASE INHIBITORS IN THE TREATMENT OF RESPIRATORY DISEASES | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2006-10-04 | — | — | EP | disclosed |
| EP-1676574-A2 | Methods for promoting survival of transplanted tissues and cells | Johnson & Johnson Vision Care, Inc. (US) | 2006-07-05 | — | — | EP | disclosed |
| WO-2006015775-A2 | EGFR KINASE INHIBITOR COMBINATIONS FOR TREATING RESPIRATORY AND GASTROINTESTINAL DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-02-16 | — | — | WO | disclosed |
| US-20060035893-A1 | Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-02-16 | — | — | US | disclosed |
| US-20060019971-A1 | Treatment of cardiovascular disease with inhibitors of p38 kinase | SCIOS INC. | 2006-01-26 | — | — | US | disclosed |
| EP-1337255-A4 | USE OF P38 INHIBITORS FOR THE TREATMENT OF INFLAMMATION-ENHANCED COUGH | SMITHKLINE BEECHAM CORP (US) | 2006-01-25 | — | — | EP | disclosed |
| US-20050163726-A1 | Pharmaceutical compositions based on novel anticholinergics and p38 kinase inhibitors | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-07-28 | — | — | US | disclosed |
| US-20050129729-A1 | Stents and intra-luminal prostheses containing map kinase inhibitors | SCIOS, INC. | 2005-06-16 | — | — | US | disclosed |
| EP-1534282-A2 | PHARMACEUTICAL COMPOSITIONS OF ANTICHOLINERGICS AND P38 KINASE INHIBITORS IN THE TREATMENT OF RESPIRATORY DISEASES | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2005-06-01 | — | — | EP | disclosed |
| EP-1496900-A2 | NEW PHARMACEUTICAL COMPOSITIONS BASED ON ANTICHOLINERGICS AND P38 KINASE INHIBITORS | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2005-01-19 | — | — | EP | disclosed |
| EP-1494645-A2 | METHOD OF TREATING MUCUS HYPERSECRETION | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2005-01-12 | — | — | EP | disclosed |
| US-20040171659-A1 | Methods for treating diabetes | SCIOS, INC. | 2004-09-02 | — | — | US | disclosed |
| US-20040162289-A1 | Methods of promoting osteogenesis | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY | 2004-08-19 | — | — | US | disclosed |
| EP-1223924-A4 | USE OF CSAIDS IN RHINOVIRUS INFECTION | SMITHKLINE BEECHAM CORP (US) | 2004-07-14 | — | — | EP | disclosed |
| US-20040122008-A1 | Treatment of pain by inhibition of p38 MAP kinase | SCIOS, INC. | 2004-06-24 | — | — | US | disclosed |
| US-20040097473-A1 | Use of p38 inhibitors for the treatment of smoke inhalation | SMITHKLINE BEECHAM CORPORATION | 2004-05-20 | — | — | US | disclosed |
| EP-0935465-B1 | NOVEL SUBSTITUTED IMIDAZOLE COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2004-04-14 | — | — | EP | disclosed |
| US-20040044020-A1 | Pharmaceutical compositions based on novel anticholinergics and p38 kinase inhibitors | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-03-04 | — | — | US | disclosed |
| WO-2004004725-A2 | PHARMACEUTICAL COMPOSITIONS OF ANTICHOLINERGICS AND P38 KINASE INHIBITORS IN THE TREATMENT OF RESPIRATORY DISEASES | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-01-15 | — | — | WO | disclosed |
| US-20030225089-A1 | Pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-12-04 | — | — | US | disclosed |
| US-20030220336-A1 | Method of treating mucus hypersecretion | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-11-27 | — | — | US | disclosed |
| WO-2003084539-A2 | NEW PHARMACEUTICAL COMPOSITIONS BASED ON ANTICHOLINERGICS AND P38 KINASE INHIBITORS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-10-16 | — | — | WO | disclosed |
| WO-2003084503-A2 | P38 KINASE INHIBITORS FOR TREATING MUCUS HYPERSECRETION_ | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-10-16 | — | — | WO | disclosed |
| EP-1337255-A2 | USE OF P38 INHIBITORS FOR THE TREATMENT OF INFLAMMATION-ENHANCED COUGH | SmithKline Beecham Corporation (US) | 2003-08-27 | — | — | EP | disclosed |
| EP-0889888-A4 | NOVEL TREATMENT FOR CNS INJURIES | SMITHKLINE BEECHAM CORP (US) | 2003-01-08 | — | — | EP | disclosed |
| WO-2002060869-A2 | USE OF P38 INHIBITORS FOR THE TREATMENT OF INFLAMMATION-ENHANCED COUGH | SMITHKLINE BEECHAM CORPORATION (US) | 2002-08-08 | — | — | WO | disclosed |
| EP-1223924-A2 | USE OF CSAIDS IN RHINOVIRUS INFECTION | SmithKline Beecham Corporation (US) | 2002-07-24 | — | — | EP | disclosed |
| US-6387898-B1 | USING IMIDAZOLE COMPOUND | SMITHKLINE BEECHAM CORPORATION | 2002-05-14 | — | — | US | disclosed |
| US-6214844-B1 | ANTIARTHRITIC AGENTS; BONE DISORDERS; ANTIINFLAMMATORY AGENTS | SMITHKLINE BEECHAM CORPORATION | 2001-04-10 | — | — | US | disclosed |
| WO-2001019322-A2 | USE OF CSAIDS IN RHINOVIRUS INFECTION | SMITHKLINE BEECHAM CORPORATION (US) | 2001-03-22 | — | — | WO | disclosed |
| US-6096739-A | Treatment for CNS injuries | SMITHKLINE BEECHAM CORPORATION (US) | 2000-08-01 | — | — | US | disclosed |
| EP-0889888-A1 | NOVEL TREATMENT FOR CNS INJURIES | SMITHKLINE BEECHAM CORPORATION (US) | 1999-01-13 | — | — | EP | disclosed |
| US-5811549-A | Process of preparing imidazole compounds | SMITHKLINE BEECHAM (US) | 1998-09-22 | — | — | US | disclosed |
| US-5716955-A | Substituted imidazole compounds | SMITHKLINE BEECHAM CORPORATION (US) | 1998-02-10 | — | — | US | disclosed |
| WO-1997035856-A1 | NOVEL TREATMENT FOR CNS INJURIES | SMITHKLINE BEECHAM CORPORATION (US) | 1997-10-02 | — | — | WO | disclosed |
| WO-1997035856-A1 | NOVEL TREATMENT FOR CNS INJURIES | SMITHKLINE BEECHAM CORPORATION (US) | 1997-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (41 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250011400-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OR PREVENTION OF SEVERE INFLUENZA | CXCL10, MAPK10, MAPK1 | MAPK14 15/4885PRKD3 813/4885MAP4K4 69/4885 |
| US-20220133704-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | ZFX, TBL1XR1, TRIM28 | MAPK14 191/4885PRKD3 154/4885MAP4K4 53/4885 |
| US-20140357638-A1 | COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE | APP, PSEN1, PSEN2 | MAPK14 4676/4885PRKD3 3771/4885MAP4K4 4048/4885 |
| US-20050163726-A1 | Pharmaceutical compositions based on novel anticholinergics and p38 kinase inhibitors | CHRM3, CHRNB1, CHRM2 | MAPK14 83/4885PRKD3 137/4885MAP4K4 92/4885 |
| US-12145981-B2 | Methods and compounds for the treatment or prevention of severe influenza | CXCL10, MAPK10, CCL11 | MAPK14 14/4885PRKD3 728/4885MAP4K4 69/4885 |
| US-20200383963-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | ZFX, TBL1XR1, RHOXF2 | MAPK14 193/4885PRKD3 134/4885MAP4K4 54/4885 |
| US-20030225089-A1 | Pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors | CHRM3, CHRM2, CHRNB1 | MAPK14 79/4885PRKD3 121/4885MAP4K4 82/4885 |
| US-20070027319-A1 | Synthesis of 4/5-pyrimidinylimidazoles via sequential functionalization of 2,4-dichloropyrimidine | DCK, DPYD, DTYMK | MAPK14 940/4885PRKD3 845/4885MAP4K4 71/4885 |
| US-11154543-B2 | P38 MAP kinase inhibitors for wound healing | MAPK1, MMP1, MAP3K1 | MAPK14 44/4885PRKD3 463/4885MAP4K4 39/4885 |
| US-20060019971-A1 | Treatment of cardiovascular disease with inhibitors of p38 kinase | MAPKAPK5, MAPK1, MAPKAPK2 | MAPK14 36/4885PRKD3 117/4885MAP4K4 32/4885 |
| US-20100274016-A1 | SYNTHESIS OF 4/5-PYRIMIDINYLIMIDAZOLES VIA SEQUENTIAL FUNCTIONALIZATION OF 2,4-DICHLOROPYRIMIDINE | DCK, DPYD, DTYMK | MAPK14 940/4885PRKD3 845/4885MAP4K4 71/4885 |
| US-20260144674-A1 | Apparatus and Methods for Drug Delivery Using Microneedles | PROKR2, SLC10A2, GLP1R | MAPK14 735/4885PRKD3 1757/4885MAP4K4 1224/4885 |
| US-20080108658-A1 | METHODS OF PROMOTING OSTEOGENESIS | MAPK1, BMP2, MAPK3 | MAPK14 23/4885PRKD3 196/4885MAP4K4 55/4885 |
| US-20040092532-A1 | Use of p38 inhibitors for the treatment of smoke inhalation | MAPKAPK2, MAPKAPK5, MAPKAPK3 | MAPK14 15/4885PRKD3 547/4885MAP4K4 67/4885 |
| US-20040162289-A1 | Methods of promoting osteogenesis | MAPK1, BMP2, MAPK3 | MAPK14 23/4885PRKD3 196/4885MAP4K4 55/4885 |
| US-20260109951-A1 | METHODS AND COMPOSITIONS FOR INDUCING HEMATOPOIETIC CELL DIFFERENTIATION | PBK, CD4, CD22 | MAPK14 1645/4885PRKD3 259/4885MAP4K4 1908/4885 |
| US-20040044020-A1 | Pharmaceutical compositions based on novel anticholinergics and p38 kinase inhibitors | CHRM3, CHRNB1, CHRM2 | MAPK14 83/4885PRKD3 137/4885MAP4K4 92/4885 |
| US-20190105311-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | ZFX, TBL1XR1, TRIM28 | MAPK14 196/4885PRKD3 176/4885MAP4K4 56/4885 |
| US-20090017036-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISORDERS | BDKRB2, EDNRB, GRK5 | MAPK14 74/4885PRKD3 308/4885MAP4K4 69/4885 |
| US-20160354375-A1 | CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES SUCH AS TAUOPATHIES | CSNK1G1, CSNK1A1, CSNK1D | MAPK14 636/4885PRKD3 128/4885MAP4K4 82/4885 |
| US-20220282254-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | ZFX, TBL1XR1, TRIM28 | MAPK14 191/4885PRKD3 154/4885MAP4K4 53/4885 |
| US-20100274015-A1 | SYNTHESIS OF 4/5-PYRIMIDINYLIMIDAZOLES VIA SEQUENTIAL FUNCTIONALIZATION OF 2,4-DICHLOROPYRIMIDINE | DCK, DPYD, DTYMK | MAPK14 940/4885PRKD3 845/4885MAP4K4 71/4885 |
| US-20190105312-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | ZFX, TBL1XR1, TRIM28 | MAPK14 191/4885PRKD3 154/4885MAP4K4 53/4885 |
| US-20240316055-A1 | METHODS FOR TREATING LEIGH SYNDROME | ECHS1, GLS2, OAT | MAPK14 4665/4885PRKD3 2960/4885MAP4K4 3657/4885 |
| US-20260034177-A1 | HUMAN FUNCTIONAL CORNEAL ENDOTHELIAL CELL AND APPLICATION THEREOF | EPCAM, CD44, SLC17A5 | MAPK14 1702/4885PRKD3 1485/4885MAP4K4 3634/4885 |
| US-20220275062-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OR PREVENTION OF SEVERE INFLUENZA | CXCL10, MAPK10, CCL11 | MAPK14 14/4885PRKD3 728/4885MAP4K4 69/4885 |
| US-20040122008-A1 | Treatment of pain by inhibition of p38 MAP kinase | OPRK1, OPRL1, MAPK3 | MAPK14 36/4885PRKD3 568/4885MAP4K4 37/4885 |
| US-20120289511-A1 | COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE | APP, PSEN1, PSEN2 | MAPK14 4676/4885PRKD3 3771/4885MAP4K4 4048/4885 |
| US-20070123516-A1 | Method of treating mucus hypersecretion | MUC1, CFTR, MAPKAPK5 | MAPK14 44/4885PRKD3 337/4885MAP4K4 89/4885 |
| US-20080039461-A1 | Treatment of pain by inhibition of p38 map kinase | OPRK1, OPRL1, MAPK3 | MAPK14 36/4885PRKD3 568/4885MAP4K4 37/4885 |
| US-20040097473-A1 | Use of p38 inhibitors for the treatment of smoke inhalation | MAPKAPK2, MAPKAPK5, MAPK1 | MAPK14 13/4885PRKD3 872/4885MAP4K4 68/4885 |
| US-10342786-B2 | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD | ZFX, TBL1XR1, TRIM28 | MAPK14 191/4885PRKD3 154/4885MAP4K4 53/4885 |
| US-11291659-B2 | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD | ZFX, TBL1XR1, TRIM28 | MAPK14 191/4885PRKD3 154/4885MAP4K4 53/4885 |
| US-20040171659-A1 | Methods for treating diabetes | SLC5A2, MAPK4, MAPK3 | MAPK14 53/4885PRKD3 232/4885MAP4K4 24/4885 |
| US-20260115177-A1 | MEDICINAL PRODUCTS AND METHODS FOR THE ALLEVIATION OF CANCER IMMUNOTHERA-PY-ASSOCIATED CYTOKINE RELEASE SYNDROME | MAPK13, MAPK11, MAPK1 | MAPK14 18/4885PRKD3 761/4885MAP4K4 64/4885 |
| US-20260132471-A1 | GENOMIC BIOMARKERS OF EARLY RECURRENCE IN COLORECTAL CANCER (CRC) | MSH2, MSH6, PMS2 | MAPK14 2308/4885PRKD3 935/4885MAP4K4 2258/4885 |
| US-20060035893-A1 | Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders | BDKRB2, EDNRB, GRK5 | MAPK14 74/4885PRKD3 308/4885MAP4K4 69/4885 |
| US-11339207-B2 | Methods and compounds for the treatment or prevention of severe influenza | CXCL10, MAPK10, MAPK1 | MAPK14 15/4885PRKD3 813/4885MAP4K4 69/4885 |
| US-20100016279-A1 | BICYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF ANDROGEN RECEPTOR ASSOCIATED CONDITIONS-155 | AR, NR5A1, CYP17A1 | MAPK14 4409/4885PRKD3 995/4885MAP4K4 3925/4885 |
| US-20160030431-A1 | COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE | APP, PSEN1, PSEN2 | MAPK14 4676/4885PRKD3 3771/4885MAP4K4 4048/4885 |
| US-20030220336-A1 | Method of treating mucus hypersecretion | MUC1, CFTR, MAPKAPK5 | MAPK14 44/4885PRKD3 337/4885MAP4K4 89/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.